Tamoxifeno e Espessamento Endometrial Assintomático

• Author(s): Amaral, N ; Robalo, R ; Fatela, A
• Date: 2008
• Persistent ID: http://hdl.handle.net/10400.17/1330
• Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
• Subject(s): Tamoxifeno; Estudos Retrospectivos; Diagnóstico
• Document Type: Article
• Language: Portuguese

Description

Tamoxifen is a first-line agent for adjuvant treatment of estrogen-receptor positive breast cancer, and is used to reduce the risk of this condition in high-risk individuals. Retrospective studies established an association between tamoxifen use, endometrial thickness and endometrial cancer. There have been many attempts to identify an effective screening program for tamoxifen-related endometrial cancer, which have led to the use of transvaginal ultrasound and invasive procedures. The use of a 5mm endometrial cut-off in vaginal ultrasound is known to raise the number of endometrial biopsies with no gain in early cancer diagnosis. A review of the scientific literature was performed in order to establish the best available evidence for endometrial evaluation of asymptomatic breast cancer patients on tamoxifen.